Insulet Corporation (PODD)

Currency in USD
154.87
-2.02(-1.29%)
Closed·
155.17+0.30(+0.19%)
·
PODD is included in our AI-picked strategies. See how they work
Fair Value
Day's Range
152.28155.90
52 wk Range
145.59354.88
Key Statistics
Prev. Close
156.89
Open
154.55
Day's Range
152.28-155.9
52 wk Range
145.59-354.88
Volume
949.14K
Average Vol. (3m)
1.2M
1-Year Change
-51.8079%
Book Value / Share
18.5
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
PODD Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
246.79
Upside
+59.35%
Members' Sentiments
Bearish
Bullish
ProTips
High shareholder yield

Insulet Corporation News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Neutral
Technical Indicators
Sell
Moving Averages
Neutral

Analyst Ratings

21 Buy
3 Hold
1 Sell
Ratings:
25 analysts
Overall Consensus
Buy

Analysts 12-Month Price Target:

Average 246.79
(+59.35% Upside)
Firm
ArticlePositionPrice TargetUpside / DownsideFrom Price TargetActionDate
William Blair
Buy---New CoverageMay 20, 2026
Benchmark
Buy250.00+61.43%-MaintainMay 11, 2026
Barclays
Sell198.00+27.85%286.00MaintainMay 08, 2026
JPMorgan
Buy275.00+77.57%340.00MaintainMay 07, 2026
Wells Fargo
Buy255.00+64.65%360.00MaintainMay 07, 2026

Insulet Corporation SWOT Analysis


Competitive Edge
Insulet's tubeless patch pump technology differentiates it in diabetes care, showing strong T2II patient preferences while navigating competition from alternative treatments
Analyst Outlook
Price targets range from $301 to $370, with an average around $326, reflecting confidence in Omnipod's technology advantages despite execution uncertainties
Market Paradox
Despite robust Q3 earnings and overwhelming analyst support with 90% Buy ratings, the stock declined amid GLP-1 drug pricing concerns and valuation questions
Growth Ambitions
Management unveiled a bold 20% three-year growth plan, surpassing Street estimates by 200-300 basis points through T2II market penetration and international expansion
Read full SWOT analysis

Insulet Corporation Earnings Call Summary for Q1/2026

  • Q1 2026 EPS of $1.42 beat estimates by 18.3%; revenue reached $761.7M, exceeding forecasts by 4.4% with 34% YoY growth driven by Omnipod sales.
  • GAAP gross margin hit 69.5% while adjusted operating margin improved 110 basis points to 17.5%, reflecting strong operational execution.
  • Stock declined 0.3% premarket to $167.02 despite earnings beat; shares down 48% over six months, trading near 52-week low of $158.35.
  • Company guided Q2-Q4 2026 EPS between $1.48-$2.02 and revenue of $788M-$935M; announced Omnipod 5 integration with FreeStyle Libre 3 Plus.
  • Management cited innovation focus and market expansion plans; acknowledged margin pressure risks from exit costs and supply chain disruptions.
Last Updated: 05/06/2026, 09:33 AM
Read Full Transcript
Insulet investor slides for Q1/2026
Insulet Q1 2026 slides
Last Update: May 06, 2026
See full investor slides

Earnings

Latest Release
May 06, 2026
EPS / Forecast
1.42 / 1.20
Revenue / Forecast
761.7M / 729.9M
EPS Revisions
Last 90 days

PODD Income Statement

Compare PODD to Peers and Sector

Metrics to compare
PODD
Peers
Sector
Relationship
P/E Ratio
35.4x8.7x−0.5x
PEG Ratio
−1.560.030.00
Price / Book
8.2x6.2x2.6x
Price / LTM Sales
3.7x3.9x3.1x
Upside (Analyst Target)
61.1%44.6%53.0%
Fair Value Upside
Unlock9.5%5.9%Unlock

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes in the United States and internationally. The company offers Omnipod platform products comprising Omnipod 5 automated insulin delivery system, which includes a proprietary AID algorithm embedded in the pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless Bluetooth communication; Omnipod DASH insulin management system that features a Bluetooth enabled pod that is controlled by a smartphone-like personal diabetes manager with a color touch screen user interface; and the Omnipod Insulin Management System. It also provides pods for Amgen for use in the Neulasta Onpro kit, which is a delivery system to help reduce the risk of infection after intense chemotherapy. The company sells its products to end-users through the pharmacy channel; and independent distributors. Insulet Corporation was incorporated in 2000 and is headquartered in Acton, Massachusetts.

Ownership

Ownership Overview

Type
Common Stock Held% of Shares OutstandingMarket Value
Mutual Funds & ETFs
40.86M58.99%6.33B
Other Institutional Investors
26.47M38.21%4.10B
Public Companies & Retail Investors
1.94M2.80%300.18M
Total
69.26M100.00%10.73B

Top Holders

Holder
% of holding
Shares Held
Date Reported
Value (In 1,000s)
The Vanguard Group, Inc.12.56%8,701,4721,347,597
BlackRock, Inc.9.20%6,373,719987,098

People Also Watch

102.69
EPAM
-0.48%
52.75
CTSH
+0.82%
1,239.91
FICO
+0.96%
160.01
IT
+1.77%

FAQ

What Is the Insulet (PODD) Stock Price Today?

The Insulet stock price today is 154.87 USD.

What Stock Exchange Does Insulet Trade On?

Insulet is listed and trades on the Nasdaq Stock Exchange.

What Is the Stock Symbol for Insulet?

The stock symbol for Insulet is "PODD."

What Is the Insulet Market Cap?

As of today, Insulet market cap is 10.73B USD.

What Is Insulet's Earnings Per Share (TTM)?

The Insulet EPS (TTM) is 4.29.

When Is the Next Insulet Earnings Date?

Insulet will release its next earnings report on Aug 06, 2026.

From a Technical Analysis Perspective, Is PODD a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.

How Many Times Has Insulet Stock Split?

Insulet has split 0 times.

How Many Employees Does Insulet Have?

Insulet has 5400 employees.

What is the current trading status of Insulet (PODD)?

As of May 25, 2026, Insulet (PODD) is trading at a price of 154.87 USD, with a previous close of 156.89 USD. The stock has fluctuated within a day range of 152.28 USD to 155.90 USD, while its 52-week range spans from 145.59 USD to 354.88 USD.

What Is Insulet (PODD) Price Target According to Analysts?

The average 12-month price target for Insulet is 246.79 USD, with a high estimate of 360 USD and a low estimate of 175 USD. 21 analysts recommend buying the stock, while 1 suggest selling, leading to an overall rating of Buy. The stock has an +59.35% Upside potential.

What Is the PODD After Hours Price?

PODD's last after hours stock price is 155.17 USD, the stock has decreased by 0.30, or 0.19%.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.